N1O1 AI control system
I found preventable ad waste, localization failure, child-inventory delivery, a missing diagnostic front door, and an IP lane that should be protected before competitors or sloppy execution weaken it. The fix is a custom AI control layer sitting above ads, funnel, NO Score, marketplace risk, and patent evidence.
You have the science. Humann has the better commercial machine. That is the problem. Your ad account has been buying attention in the wrong places, in the wrong languages, and without the measurement front door that turns a cold visitor into a qualified N1O1 buyer.
Right now, too much traffic is being asked to do the hardest thing first: believe a product claim. A cold visitor clicks an ad, lands in a product or content path, and has to decide whether nitric oxide matters to them before the site has helped them understand their own status. That creates friction. It also makes ads look weaker than they should, because the funnel is not sorting curiosity into personal need.
Brazil is the easiest example of the account-control problem. The market speaks Portuguese and the ads/videos were English. The placement data also shows adult nitric oxide spend landing on kids, toys, cartoons, and family entertainment. That is not expansion. That is unmanaged spend.
NO Score, the Nitric Oxide Score front door, fixes the order of the conversation. It does not start by asking people to buy. It starts by helping them see whether nitric oxide is personally relevant: their likely NO status, their NO Age, which pathway may be weak, and which product or protocol fits that pathway.
That changes the job of the website. The first click no longer has to sell everything. It has to get the visitor to answer a short assessment. From there, N1O1 gets segmentation, product fit, retest timing, CRM follow-up, and a data loop that tells the ad system which traffic is actually qualified.
I took the live n1o1.iaib.ai flow. It is not asking for a login before the assessment. It moves straight into an 8-click pathway check: age decline, exercise, diet, oral bacteria, vascular status, sleep, stress, and medications. The conversion is not the score at the end. The conversion happens while the visitor realizes the problem is personal.
The fix is not another marketing memo. The fix is to stop the waste, make NO Score the front door, and install a custom AI control layer that watches ads, language, placements, assessment behavior, product fit, marketplace risk, and patent evidence every week.
The older N1O1 folder adds a historical record from January 2026: 406 local files, old Google Ads Transparency captures, Semrush ad exports, YouTube channel exports, campaign workbooks, spend rows, site captures, HAR files, brand-protection reports, and the prior forensic audit output.
| Historical lane | What the file set shows | Why it matters now |
|---|---|---|
| Spain YouTube placements | $562,093.89 in deduped channel spend, with top rows including Mejores Juguetes, TOYS on the go!, MikelTube, and Pocoyo. | This was not a small test. It was a large language and inventory-control failure. |
| Brazil YouTube placements | $54,568.92 in deduped numeric spend, with top rows including Sarah de Araujo, Tina Pontes, ValentinaPontesofc, Gato Galactico, and Kids Diana Show. | Brazil speaks Portuguese. Paying for English medical-adjacent ads there is account mismanagement. |
| U.S. kids inventory | $214,148.38 in deduped U.S. YouTube channel spend from the historical export set. | The U.S. problem is not language. It is audience and placement quality. |
| 2024 operating drag | Historical report records YTD 2024 advertising and marketing at $1,652,310.17, Amazon advertising at $688,779.83, and November 2024 reported ROAS at 0.31. | This was a structural leakage pattern before the June 2026 market-share gap showed up. |
| Global targeting | The old language-mismatch report says the ad location filter showed campaigns set to run Anywhere, eligible across 200+ countries and territories. | That explains how English ads reached Brazil, Spain, Mexico, Chile, Argentina, Europe, and other markets without localization. |
| Chambers Group asset risk | Old reports identify a location asset tied to The Chambers Group in Beverly Hills and call out misdirected get-directions or call clicks. | That is not a media-buying nuance. It is an account-control failure. |
| NO Score front door | January 2026 N1O1 working pages describe The NO Score Widget, NO Age, subscription path, and Digital Twin tracking. The Dec 2025 clinical-platform snapshot includes widget docs, scoring integrations, consent, dashboards, and embeddable assessment assets. | The missing conversion mechanism was not just an idea. It was already represented in working product files. |
| Patent package | April 2026 patent materials cover AI-optimized NO therapy, smartphone NO assessment, NO digital twin, and microbiome-guided probiotic selection. | The commercial fix and the IP strategy point to the same asset: measurement, pathway scoring, product fit, and retesting. |
The historical data changes the tone: this is not a one-month anomaly. The same failure pattern appears across old exports, current market data, and the current ad-system comparison.
Humann is not just bigger. In the reviewed exports, it has more paid-search coverage, more buyer-language copy, a wider landing-page map, and a tighter social/display footprint. N1O1 is carrying stronger scientific authority, but the account is buying reach before the visitor has a clear diagnostic reason to act.
449.3M U.S. impressions, $3.93M ad-intelligence spend, 328 publishers, 230 creatives, 95.69% video spend, and 99.83% programmatic buying.
Read: broad reach, heavy video, many publishers, fewer creative variants, and a top campaign holding 86.55% of spend.
139.3M U.S. impressions, $1.07M ad-intelligence spend, 48 publishers, 306 creatives, 80.65% social spend, and more distributed campaign weight.
Read: fewer places, more creative variants, more social-heavy execution, and a top campaign holding 48.01% of spend.
| Lane | Humann | N1O1 | What it means |
|---|---|---|---|
| Copy language | SuperBeets, beet benefits, heart, blood pressure, doctor, cardiologist proof | Nitric oxide, Dr. Bryan authority, lozenges, vitality, skincare, science | Humann translates the need into buyer language more often. |
| Landing pages | Traffic spread across TV, chews, superfood, collections, product pages, and offer pages | Top paid page carries 56.43% of paid-search page traffic | N1O1 has too much landing-page concentration. |
| Publisher spread | 48 publishers in the U.S. comparison | 328 publishers in the U.S. comparison | N1O1 needs tighter placement control and placement-quality scoring. |
| Campaign shape | Top campaign at 48.01% of spend | Top campaign at 86.55% of spend | N1O1 looks too dependent on one broad mixed-product message. |
What this says: Humann is turning category demand into cleaner buyer pathways. N1O1 is asking the market to believe the science before the funnel explains the visitor's own deficiency.
These are the actions I would require from the ad operator within 48 hours.
| Region | Issue | Ad-intelligence waste signal | Action |
|---|---|---|---|
| Spain | English delivery into Spanish market and kids/toy channels | $562,093.89 YouTube channel placement waste in audit set | Pause and localize before relaunch |
| Brazil | English paid search and reviewed English videos in Portuguese-speaking market | $54,568.92 YouTube channel placement waste plus 40.1M later export impressions | Pause unless Portuguese flow exists |
| United States | Adult cardiovascular supplement inventory delivered on kids channels | $214,148.38 kids inventory misalignment | Apply negative placement list |
| India / Southeast Asia / South Africa | Programmatic reach with weak localization and placement controls | $101,400 in audit set across these lanes | Do not scale until the market, language, offer, and landing page match. |
These channels are not buyer intent for N1O1. They are places where spend can disappear while reports still show reach.
| Placement | Evidence read | Directive |
|---|---|---|
| Mejores Juguetes | Spain toy placement, $84,430.63 in one export and $157,784.08 in the larger Spain export | Block |
| Pocoyo Espanol Canal Oficial | Spain cartoon placement, $73,594.14 in one export and $84,495.90 in larger export | Block |
| The Supa Strikas - Kids Soccer Cartoon | South Africa kids cartoon placement, 4.14M impressions and $24,860 spend | Block |
| Toys and Colors | U.S. kids placement, $30,399.88 spend | Block |
| Like Nastya family of channels | U.S. kids placements including Like Nastya ESP, AE, Show, and main channel | Block |
| Diana Kids / Kids Diana / Diana Bebe | U.S. and Brazil kids placements | Block |
| Sarah de Araujo / Tina Pontes / ValentinaPontesofc | Brazil child/family placement group | Block |
Blunt read: N1O1 should not pay to show adult nitric oxide supplement ads to kids watching cartoons, toy videos, and child entertainment.
If an operator says the account is fixed, require exports. Screenshots are not enough by themselves. The account has to prove where spend went, who could change settings, what auto-applied, which assets were live, and what changed after the audit.
The historical materials describe a location-asset and routing risk tied to The Chambers Group in Beverly Hills. I would not let the operator explain that away verbally. I would require the export.
| Export | What it proves | Action |
|---|---|---|
| Location assets | Every business profile, address, map route, and location extension connected to the account. | Delete any agency-owned or agency-routed location path. |
| Call assets | Every phone number tied to ads, call buttons, call reporting, or mobile extensions. | Route only to N1O1-controlled numbers. |
| Click-type report | Clicks on calls, get directions, location details, sitelinks, lead forms, and website visits. | Quantify whether N1O1 paid for agency-routed actions. |
| Change history | Who added, approved, auto-applied, paused, or removed those assets. | Assign responsibility and lock permissions. |
The point is not blame for sport. The point is governance. A seven-figure science brand cannot let platform defaults, agency convenience, or vanity reach decide where medical-adjacent spend goes.
The ad waste and the marketplace risk are connected. If N1O1 does not control the customer journey, search path, seller path, and claim path, other people can define the brand around it.
| Risk | Why it matters | Control record | Fix |
|---|---|---|---|
| Unauthorized marketplace listings | They can confuse customers, pull demand away from the official funnel, and create safety risk. | Amazon, eBay, Google Shopping, marketplace screenshots, and seller IDs. | Official storefronts, authorized seller list, monitoring, and takedown process. |
| Capsule-positioning conflict | If fake or unauthorized capsules appear official, they contradict the scientific story around nitric oxide gas. | Marketplace capture and product-photo record. | Brand registry, counterfeit report process, and official product explainer. |
| Generic product journey | Cold buyers see products before they understand their own NO status. | Landing-page and funnel path export. | NO Score first, product second, retest third. |
| Public-page timing | Working pages tied to IP strategy should stay controlled until filing strategy is settled. | Robots, meta, headers, and search-index record. | Keep working pages non-indexed and filing-aligned. |
This is where Dustin's system fits: not another ad vendor, but a control layer that watches sellers, claims, ads, placements, landing pages, and NO Score outcomes together.
Paid traffic should not go straight into generic product browsing. It should go into a diagnostic relationship. The live n1o1.iaib.ai flow gives N1O1 the front door it is missing: NO Score, pathway logic, recommendation, retest, and first-party data.
This is the plain reason it works: the visitor is not thinking about a coupon code. They are thinking about the mouthwash on their bathroom counter, their age, their blood pressure, their exercise habits, and the weak pathway they just identified with their own clicks.
| Current funnel behavior | NO Score behavior | Why Nathan should care |
|---|---|---|
| Cold visitor sees product claims first. | Visitor learns whether nitric oxide support is personally relevant. | The sale starts from self-recognition, not belief in an ad. |
| Traffic source is mostly media reporting. | Traffic source connects to pathway, score, product fit, and retest behavior. | The account learns which ads produce qualified biology, not just clicks. |
| Brazil and Spain can receive the same English message. | Each market requires language-matched assessment, landing page, and follow-up. | Localization becomes a system rule, not a later complaint. |
| Humann competes on buyer language. | N1O1 competes on measurement, pathway, and science translated into action. | This is a better battlefield for Dr. Bryan's authority. |
The old N1O1 working pages described The NO Score Widget, NO Age, pathway scoring, subscription path, and Digital Twin tracking. The Dec 2025 clinical-platform snapshot and attached platform notes show the deeper build: multi-compartment PK/PD modeling, plasma/tissue/RBC nitrite dynamics, wearable NO Activity Score, AI clinical tooling, patient prescreening, consent generation, dashboards, monitoring, alerts, analytics, offline sync, and embeddable JavaScript/CSS assets.
That matters because this is not a request to invent a quiz after the fact. The better front door already existed in the N1O1 workstream. The commercial mistake was leaving it outside the main demand-capture machine while broad traffic kept flowing into generic product paths.
The assessment should ask which mouthwash brand the person actually uses because that is the moment the funnel becomes personal. They are not thinking about a score. They are thinking about the bottle on their bathroom counter.
That is also where N1O1 needs precision. Saying "antiseptic mouthwash" is defensible. Naming Listerine as the specific NO killer is a different risk profile because the published data is stronger against chlorhexidine and CPC than it is against essential-oil Listerine.
| Product class | Published read | What the assessment should say |
|---|---|---|
| Chlorhexidine | Repeatedly tied to disruption of nitrate-reducing oral bacteria, salivary/plasma nitrite effects, and blood-pressure pathway concerns. | High risk: strong published support for nitrate-pathway disruption. |
| CPC / antibacterial mouthwash | Woessner separated stronger antibacterial/chlorhexidine effects from control and Listerine-style antiseptic treatment after nitrate load. | Moderate risk: treat as pathway-disruptive unless product data says otherwise. |
| Listerine / essential oils | Woessner tested Listerine directly. Mitsui found essential-oil mouthwash had little effect on nitrate-reducing activity. Liu 2023 reported many nitrate-reducing bacteria were not reduced after Listerine while chlorhexidine showed stronger disruption. | Lower risk: do not call it the same as chlorhexidine or CPC. |
The stronger position is not "all mouthwash is the same." The stronger position is "tell people the truth about their specific mouthwash, then show them the N1O1 product path that fits their actual risk."
CardioSmile benefits when consumers stop using the wrong oral-care products. That makes broad podcast claims about a named competitor more sensitive than general nitric-oxide education. The assessment lowers that risk because it is specific, study-mapped, and product-class aware.
The legal exposure is not fixed by being less forceful. It is fixed by being more precise. The NO Score flow can say what the literature supports, by ingredient and product class, while still making the commercial answer obvious.
I am not proposing to be a marketing consultant. I am proposing to train and install the custom AI control system that should sit above N1O1's ads, funnel, NO Score data, marketplace risk, and patent evidence.
| Agent | What it watches | Why it matters |
|---|---|---|
| Ad waste agent | countries, language, placements, publishers, spend changes, auto-apply settings | Catches Brazil/Spain/kids-inventory problems before they scale. |
| NO Score agent | assessment completion, pathway distribution, product fit, retest behavior | Turns traffic into owned diagnostic data. |
| Competitor agent | Humann copy, keywords, landing pages, product emphasis | Shows where N1O1 is being out-captured. |
| Brand protection agent | eBay, Amazon, counterfeit capsule risk, unauthorized sellers | Protects scientific credibility and customer safety. |
| IP evidence agent | patent packet, deadline records, public-page posture, counsel checklist | Keeps the measurement layer aligned with filing strategy. |
This is the practical sequence I would put in front of N1O1. Stop the waste first, then rebuild the data path, then train the AI layer to keep it from happening again.
This is not a marketing-consulting fee. It is an account-control, data, AI, and IP-defense build. The audit already points to minimum known waste near seven figures. The price is anchored to preventing repeat loss and turning the NO Score layer into a defensible operating asset.
The patent materials point to the same conclusion as the market data. The control point is not another supplement claim. It is the measurement and personalization layer around nitric oxide.
The business point is clear: the measurement layer is the category-control point.
Dr. Bryan, I checked the data. Humann is not beating you because they know more nitric oxide science. They are beating you because their demand-capture system is more mature.
Your ads and site are asking cold visitors to believe the product before they understand their own nitric oxide status. That is backwards.
I took the assessment at n1o1.iaib.ai. Eight clicks. No login wall. It makes the person think about their own age, diet, exercise, oral bacteria, sleep, stress, medications, and mouthwash. The score at the end is the receipt. The conversion happens during the assessment.
NO Score, the Nitric Oxide Score front door, fixes the order of the conversation. It turns curiosity into a personal status check, that status check into pathway understanding, pathway understanding into product fit, and product fit into follow-up data.
It also fixes a real podcast risk. Your website says antiseptic mouthwash, which is defensible. The podcast clips naming Listerine are more exposed because the published data separates essential-oil Listerine from chlorhexidine and CPC. The assessment can tell each user the truth about their exact mouthwash and still route them to the right N1O1 product.
I am not asking to be your marketing consultant. I am proposing to build and train the custom AI control system that should sit above ads, NO Score, CRM, competitor tracking, marketplace protection, and patent evidence.
If you want to win the category, stop only buying traffic. Own the system that tells people why they need nitric oxide, which pathway is broken, what product fits, and what changed after they used it.
This page is built from paid market, ad, YouTube placement, paid-search, page, patent, and public-site data.
Brazil paid-search copy is English. Brazil videos were directly reviewed and confirmed English, not Portuguese.
Audit set identifies $970,797.07 minimum known waste.
YouTube channel exports show N1O1 placements on toy, cartoon, and child/family channels including Mejores Juguetes, Pocoyo, Toys and Colors, Like Nastya, Kids Diana, and Supa Strikas.
Historical materials identify a Chambers Group location-asset and routing risk. The operator should export location assets, call assets, click-type rows, linked accounts, and change history, then remove any agency-owned route.
n1o1.iaib.ai is live with assessment-first NO Score positioning. n1o1.com remains product/shop/content-first rather than assessment-first. The older N1O1 working files also describe The NO Score Widget, NO Age, pathway scoring, Digital Twin tracking, and embeddable assessment assets.
Woessner 2016 tested Listerine, Cepacol, chlorhexidine, and water after nitrate load. Mitsui 2017 found essential-oil mouthwash had little effect on nitrate-reducing activity while chlorhexidine inhibited the V. dispar band. Liu 2023 found many nitrate-reducing bacteria were not reduced after Listerine while chlorhexidine showed stronger disruption.
The patent packet points to the platform layer: NO Score, smartphone assessment, AI dosing, digital twin modeling, and microbiome-guided selection.
The workbook records Humann at 204 paid-search rows, 160 unique keywords, and 10.5k estimated paid-search traffic vs N1O1 at 32 rows, 29 keywords, and 836 estimated paid-search traffic.
U.S. comparison exports show N1O1/NO2U with 328 publishers and 230 creatives vs Humann with 48 publishers and 306 creatives. N1O1/NO2U is heavier on video and broader publisher spread.
Brand-protection reports identify unauthorized marketplace and capsule-positioning risk. This belongs in the weekly AI control system.
The waste and spend record is strong enough to freeze the weak lanes, rebuild the funnel, and install weekly account monitoring.